Search This Blog

Showing posts with label adverse drug reactions. Show all posts
Showing posts with label adverse drug reactions. Show all posts

Monday, 2 March 2015

New UK initiative from 2nd March on driving and legal or illegal drugs

2nd March 2015: 
It was previously an offence to drive whilst impaired through drink or drugs.


New regulations in England and Wales, in place from 2nd March 2015, aim to reduce risk of RTAs caused by drivers who are taking illegal drugs while driving, or legal drugs which impair their ability to drive. 

It is now an offence, as it has been for alcohol, to drive with certain drugs above a specified level in the blood. Sixteen legal (see Table below) and illegal drugs are covered by the law, including cannabis, cocaine, ecstasy and ketamine. 

There is now a zero tolerance approach to 8 drugs most associated with illegal use. There will also be a 'road safety risk based approach' to 8 prescribed drugs most associated with RTA risk. It remains the "driver’s responsibility to decide whether they consider their driving is, or they believe might be, impaired on any given occasion." (page 7)

Recreational drugs are well-established as causes of road traffic accidents (RTAs). DrinkAware lists several important reasons why alcohol leads to accidents. Alcohol
  • affects judgement and reasoning
  • slows down reactions
  • upsets sense of balance and coordination
  • impairs vision and hearing
  • makes users lose concentration and feel drowsy.
DrinkAware note legal limits for alcohol in the breath as 35 microgram/100 
mL for England and Wales (80 milligram/100 ml in blood) and lower at 22 microgram/100 mL in breath for Scotland (50 milligram/100 ml in blood).

Cannabis use also increases driving risk in several ways and has, for example, been implicated in 1 in 4 RTAs in France.  Furthermore alcohol and cannabis are often used together and in combination can increase risk of a road traffic accident.

For recreational drugs, safety when driving may be impaired both during use and during drug withdrawal.  

Several commonly prescribed drugs are also expected to reduce alertness and lead to increased risk of road traffic accidents.

People who are having difficulty sleeping may already when awake have reduced ability to concentrate on key tasks, including driving. Poor quality of sleep combined with night sedation may  together reduce alertness further.

Other drugs may have sedative effects as a less obvious action – for example opiate like drugs used to treat pain.

Patients who are concerned about the effects of their prescribed drugs on their safety while driving should consult their pharmacist of medical adviser.

The Government's website notes that:
 'the new law provides a medical defence if you’re taking your medicine in accordance with instructions – either from a healthcare professional or printed in the accompanying leaflet – provided, of course, you’re not impaired.'

It also notes that:
'If you’re driving and you’re on prescription medicine, it may therefore be helpful for you to keep some evidence of this with you in case you’re stopped by the police.'

The following blood level limits for prescription drugs are noted to be:

‘Medicinal’ drugs (risk based approach) Threshold limit in blood
amphetamine 250µg/L
clonazepam 50µg/L
diazepam 550µg/L
flunitrazepam 300µg/L
lorazepam 100µg/L
methadone 500µg/L
morphine 80µg/L
oxazepam 300µg/L
temazepam 1,000µg/L


UK Government's drug driving website

Drug Driving: Guidance for Healthcare Professionals

DrinkAware website

Sunday, 2 November 2014

Helping to improve safety in the use of medicines in Sub-Saharan Africa.


Press Release: 00.00h Monday 3rd November 2014


Medicines have powerful effects to help patients. However medicines also have the potential to cause powerful harmful effects. Education on how to ensure safe and effective use of medicines is therefore vitally important for patients and health services.
An International Symposium on Medicines and Patient Safety is being held in Kigali, Rwanda at the College of Medicine and Health Sciences (CMHS) on Wednesday 5th November 2014, followed by an international videoconference on Prescribing Skills and on Pharmacovigilance on Thursday 6th November with contributors from the UK and the WHO. The meeting will include talks on medicines and communicable and non-communicable diseases by national and international clinical and policy experts from Rwanda, South Africa, USA and the UK.
The Symposium is being held in partnership with Pharmacology for Africa, a consortium of 8
Sub-Saharan countries supported by the International Union of Pharmacology, and led by Professor Douglas Oliver and Professor Christiaan Brink, from South Africa, both of whom will be speaking at the meeting.The 3 major themes of the symposium are: educating health professionals in safe and effective use of medicines; regulating drugs, including pharmacovigilance and quality of medicines, reducing harm from high risk medicines and in patients with high risk conditions.
Speakers will discuss ways to reduce risk from medicines for treating children and expectant mothers, preventing disorders of the heart and stroke, and for treating cancer, retroviral disease and kidney disease. There will also be round table discussions not only on prescribed medicines, but also on the risks of over-the-counter and traditional medicines.
Pharmacist Dr Kayumba said: “The Symposium is timely in building on strategy in Rwanda on pharmacovigilance and on developing our undergraduate and postgraduate educational systems for good practice in use of medicines.”
Physician Dr Musabeyezu added: “The Symposium will also provide important updates for doctors, pharmacists and nurses from Referrral and District Hospitals from throughout Rwanda on reducing risk of harm from high risk medicines often used for high risk diseases”. 
Clinical Pharmacologist Professor Singer noted: “Partnership with Pharmacology for Africa brings important opportunities to improve patient health and safety through engaging with a wide range of international experts in education, training, clinical practice and research aimed at best practice in use of medicines.
The symposium is supported by the World Health Organisation, Pharmacology for Africa, the International Union of Basic and Clinical Pharmacology, Partners in Health, the Rwanda Social Security Board and the University of Rwanda College of Medicine and Health Sciences

Information for Editors
For further information, including to arrange an interview with the organisers, and for a press pass to attend the symposium on 5th November 2014, email ISMPS@gmail.com